Please login to the form below

Not currently logged in
Email:
Password:

chronic low back pain

This page shows the latest chronic low back pain news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

The 16-week study in patients with osteoarthritis (OA) pain evaluated subcutaneous administration of tanezumab, one of a new class of nerve growth factor (NGF) inhibitor drugs. ... In addition to OA pain, the biologic is being evaluated for chronic low

Latest news

  • FDA fast-tracks Pfizer and Lilly's tanezumab FDA fast-tracks Pfizer and Lilly's tanezumab

    pain. The US FDA gave the status to tanezumab as a treatment for osteoarthritis and chronic low back pain in patients who cannot adequate pain relief or cannot tolerate currently available ... potential. They estimate that there are more than 27 million

  • FDA halts study of Teva and Regeneron's pain drug fasinumab FDA halts study of Teva and Regeneron's pain drug fasinumab

    The FDA placed a clinical hold on a phase IIb trial of Teva and Regeneron's nerve growth factor (NGF) inhibitor fasinumab in chronic lower back pain on safety concerns. ... We look forward to working with global health authorities to advance this

  • Pfizer sales down but oncology shows promise Pfizer sales down but oncology shows promise

    pegged back by the termination of a collaboration with Boehringer Ingelheim on chronic obstructive pulmonary disease (COPD) treatment Spiriva (tiotropium) in some markets. ... The company has also joined forces with Lilly to develop anti-nerve growth

  • Lilly's Cymbalta approved for new use

    osteoarthritis and chronic lower back pain. ... The marketing application for the latest indication was supported by relatively small clinical studies enrolling about 600 patients with chronic low back pain or chronic pain due to osteoarthritis who

  • FDA advisors back expanded Cymbalta use

    broader population after reviewing safety and efficacy data from studies testing the drug for chronic low back pain and for chronic pain due to osteoarthritis of the knee. ... For people living with chronic low back pain and chronic pain due to

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    prostate cancer. 2, 400. Pfizer / Lilly. Co-development. Shared development of tanezumab (anti-nerve growth factor) for the treatment of osteoarthritis, chronic low back and cancer pain. ... hyperactivity disorder, pain, urology and allergy. 1, 600.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics